- Volume 15 Issue 18
DOI QR Code
Neuroendocrine tumors in the Iran Cancer Institute: Predictive Factors of Patient Survival
- Sadighi, Sanambar (Department of Internal Medicine, Cancer Research Center, Tehran University of Medical Sciences) ;
- Roshanaee, Ghodratollah (Biostatistics Department, Hamadan University of Medical Sciences) ;
- Vahedi, Saba (Department of Internal Medicine, Cancer Research Center, Tehran University of Medical Sciences) ;
- Jahanzad, Easa (Department of Pathology, Cancer Research Center, Tehran University of Medical Sciences) ;
- Mohagheghi, Mohammad Ali (Department of Surgical Oncology, Cancer Research Center, Tehran University of Medical Sciences) ;
- Mousavi-Jarahi, Alireza (Department of Social Medicine, Shahid Beheshti University of Medical Sciences)
- 발행 : 2014.10.11
Background: Neuroendocrine tumors have widespread and different clinical presentations and prognoses. This study was conducted to assess their survival time and prognostic factors in Iran. Materials and Methods: In a retrospective cohort study, 189 patients diagnosed of having neuroendocrine carcinoma were chosen. The tumor and clinical characteristics of the patients were modeled with a Cox proportional hazard approach. Survival was assessed using Kaplan-Meyer curves. Results: Crude median survival time was 30 months. Women survived longer than men (the median survival time for women was 40 and for men was 24 months). Age (<60 vs >60 years old with hazard ratio (HR) of 2.43, 95% CI 1.3-4.5), primary pathology report (carcinoid vs. others with HR 5.85 cm, 95% CI 2.4-14.3), tumor size cm (for 5-10, HR of 3.1, 95% CI 1.6 and for >10 HR of 8.2, 95% with 95% CI 3.1-21.9), and chemotherapy with single drug (taking vs. not taking with a HR 2.2, 95% CI 1.1-4.8) had significant effects on overall survival of patients. Conclusions: Survival time in patients with neuroendocrine carcinomas is related to demographics, clinical characteristics, tumor histology, and subtype specific treatment.
- Al-khafaji B, Noffsinger A, Miller M, et al (1999). Immunohistologic analysis of GI and pulmonary carcinoid tumors. Hum Pathol, 29, 992.
- Bernick P, Klimstra S, Shia Jea (2004). Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum, 47, 163-9. https://doi.org/10.1007/s10350-003-0038-1
- Brenner B, Shah M, Gonen M (2004). Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer, 90, 1720-6.
- Demirci U, Coskun U, Karaca H, et al (2014). Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 15, 1581-4. https://doi.org/10.7314/APJCP.2014.15.4.1581
- Durante C, Boukheris H, Dromain C, et al (2009). Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer, 16, 585-97. https://doi.org/10.1677/ERC-08-0301
- Fujii H, Aotake T, Horiuchi T et al (2001). Small cell carcinoma of the gallbladder: a case 45 report and review of 53 cases in the literature. Hepatogastroenterology, 48, 1588-93.
- Galanis E, Frytak S, Lloyd R (1997). Extrapulmonary small cell carcinoma. Cancer, 79, 1729-36. https://doi.org/10.1002/(SICI)1097-0142(19970501)79:9<1729::AID-CNCR14>3.0.CO;2-#
- Garcia-Carbonero R, Capdevila J, Crespo-Herrero G (2010). Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the national cancer registry of Spain (RGETNE). Ann Oncol, 21, 1794-803. https://doi.org/10.1093/annonc/mdq022
- Harkema J, Jones S, Naydan D, Wilson D (1992). An atypical neuroendocrine carcinoma in the lung of a beagle dog. Vet Pathol, 29, 175-9. https://doi.org/10.1177/030098589202900211
- Junker K, Wiethege T, Muller K (2000). Pathology of small-cell lung cancer. J cancer Res clin oncol, 7, 361-8.
- Kang H, O'Connell J, Leonardi M (2007). Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis, 22, 183-9.
- Kulve M, Mayer R (1999). Carcinoid tumors. N Engl J Med, 340, 858-68. https://doi.org/10.1056/NEJM199903183401107
- Lee S, Lee J, Ryu M (2007). Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol, 46, 846-51. https://doi.org/10.1080/02841860601071893
- Medrano-Guzman R, Lopez-Garcia SC, Torres-Vargas S, Gonzalez-Rodriguez D, Alvarado-Cabrero I (2011). Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival. Cirugia y Cirujanos, 79, 459-564.
- Modlin I, Lye K, Kidd M (2003). A 5-decade analysis of 13, 715 carcinoid tumors. Cancer, 97, 934-59. https://doi.org/10.1002/cncr.11105
- Modlin I, Oberg K, Chung D, et al (2008). Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 9, 61-72. https://doi.org/10.1016/S1470-2045(07)70410-2
- Moertel C, Kvols L, O'Connell M (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 68, 227-32. https://doi.org/10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I
- Sadighi S, Jahanzad I, Ghadirian L, et al (2013). Assessing the prevalence and characteristics of neuroendocrine tumors in patients attending Tehran Imam Khomeiny referral hospital. J Mazand Univ Med Sci, 23, 232-6.
- Sorbye H, Welin S, Langer SW, et al (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol, 24, 152-60. https://doi.org/10.1093/annonc/mds276
- Wang Y-h, Lin Y, Xue L, et al (2012). Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord, 12, 30-9. https://doi.org/10.1186/1472-6823-12-30
- Wu B, Hu Y, Sun J, et al (2014). Analysis on the characteristics and prognosis of pulmonary neuroendocrine tumors. Asian Pac J Cancer Prev, 15, 2205-10. https://doi.org/10.7314/APJCP.2014.15.5.2205
- Yao J, Hassan M, Phan A, et al (2008). One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 26, 3063-72. https://doi.org/10.1200/JCO.2007.15.4377
- Yocel B, Babakan NAKanan T, Ayeren A (2013). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev, 14, 6687-92. https://doi.org/10.7314/APJCP.2013.14.11.6687
- Zeng YJ, Liv L, We H, et al (2013). Clinicopathologic features and prognosis of GIP neuroendocrine tumors:Analysis from a single institution. Asian Pac J Cancer Prev, 14, 5775-81. https://doi.org/10.7314/APJCP.2013.14.10.5775